Market open
Avidity Biosciences/$RNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Avidity Biosciences
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Ticker
$RNA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
391
Website
RNA Metrics
BasicAdvanced
$3.7B
-
-$2.89
1.02
-
Price and volume
Market cap
$3.7B
Beta
1.02
52-week high
$49.81
52-week low
$21.56
Average daily volume
1.3M
Financial strength
Current ratio
15.735
Quick ratio
15.607
Long term debt to equity
0.208
Total debt to equity
0.477
Management effectiveness
Return on assets (TTM)
-21.60%
Return on equity (TTM)
-33.47%
Valuation
Price to revenue (TTM)
312.106
Price to book
2.56
Price to tangible book (TTM)
2.56
Price to free cash flow (TTM)
-11.045
Growth
Revenue change (TTM)
13.99%
Earnings per share change (TTM)
-0.63%
3-year revenue growth (CAGR)
5.33%
3-year earnings per share growth (CAGR)
0.47%
What the Analysts think about RNA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Avidity Biosciences stock.
RNA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RNA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Avidity Biosciences stock?
Avidity Biosciences (RNA) has a market cap of $3.7B as of March 19, 2025.
What is the P/E ratio for Avidity Biosciences stock?
The price to earnings (P/E) ratio for Avidity Biosciences (RNA) stock is 0 as of March 19, 2025.
Does Avidity Biosciences stock pay dividends?
No, Avidity Biosciences (RNA) stock does not pay dividends to its shareholders as of March 19, 2025.
When is the next Avidity Biosciences dividend payment date?
Avidity Biosciences (RNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Avidity Biosciences?
Avidity Biosciences (RNA) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.